CRSP — Crispr Therapeutics AG Cashflow Statement
0.000.00%
Last trade - 00:00- $6.29bn
- $4.57bn
- $37.31m
- 55
- 12
- 86
- 50
Annual cashflow statement for Crispr Therapeutics AG, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -349 | 378 | -650 | -154 | -366 |
| Depreciation | |||||
| Non-Cash Items | 67.9 | 116 | 110 | 67 | 47.9 |
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 33.4 | 26.9 | 19.8 | -194 | 156 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -238 | 539 | -496 | -260 | -143 |
| Capital Expenditures | -18.4 | -81.7 | -37.2 | -12 | -1.9 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -523 | -954 | -221 | 387 | -279 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -541 | -1,035 | -259 | 375 | -280 |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 1,016 | 251 | 38.6 | 62.7 | 332 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 237 | -246 | -716 | 177 | -91.3 |